Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo

Leukemia. 2013 Nov;27(11):2262-4. doi: 10.1038/leu.2013.138. Epub 2013 May 3.

Authors

R Soderquist¹, D J P Bates, A V Danilov, A Eastman

Affiliation

¹ 1] Department of Pharmacology and Toxicology, Giesel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH, USA [2] Norris Cotton Cancer Center, Giesel School of Medicine at Dartmouth, One Medical Center Drive, Lebanon, NH, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Biphenyl Compounds / pharmacology*
Contraceptive Agents, Male / pharmacology*
Drug Resistance, Neoplasm / drug effects*
Gossypol / pharmacology*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Nitrophenols / pharmacology*
Piperazines / pharmacology
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Proto-Oncogene Proteins c-bcl-2 / metabolism
Stromal Cells / drug effects*
Stromal Cells / pathology
Sulfonamides / pharmacology*
Tumor Cells, Cultured

Substances

ABT-737
Biphenyl Compounds
Contraceptive Agents, Male
Nitrophenols
PMAIP1 protein, human
Piperazines
Proto-Oncogene Proteins c-bcl-2
Sulfonamides
Gossypol

Grants and funding